Wide Ranks

AADI

Aadi Bioscience, Inc.

2.28

Top Statistics
Market Cap 56 M Forward PE -1.82 Revenue Growth 21.00 %
Current Ratio 4.89 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -246.06 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.0860 Enterprise / Revenue -0.2180 Price To Sales Trailing12 Months 2.24
Profitability
Profit Margins -246.06 % Operating Margins -149.40 %
Balance Sheet
Total Cash 62 M Total Cash Per Share 2.54 Total Debt 946000
Total Debt To Equity 1.37 Current Ratio 4.89 Book Value Per Share 2.80
All Measures
Short Ratio 238.00 % Message Board Id finmb_430225247 Shares Short Prior Month 283524
Return On Equity -0.6595 City Pacific Palisades Uuid dc15d255-5620-3e50-9851-9151504cc320
Previous Close 2.31 First Trade Date Epoch Utc 1 B Book Value 2.80
Beta 0.3690 Total Debt 946000 Volume 77683
Price To Book 0.8149 Last Split Date 1 B Fifty Two Week Low 1.21
Total Cash Per Share 2.54 Total Revenue 25 M Shares Short Previous Month Date 1 B
Target Median Price 1.88 Audit Risk 3 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -149.40 % Target Mean Price 1.88
Net Income To Common -61687000 Short Percent Of Float 0.0154 Implied Shares Outstanding 24 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 130110
Average Volume10days 130110 Total Cash 62 M Next Fiscal Year End 1 B
Revenue Per Share 0.9290 Held Percent Insiders 0.0996 Ebitda Margins -252.87 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 2.31 Target Low Price 1.75
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.06 Open 2.33
Free Cashflow -35620500 State CA Dividend Yield 0.00 %
Return On Assets -0.3527 Time Zone Short Name EST Board Risk 6
Trailing Eps -2.28 Day Low 2.27 Address1 17383 Sunset Boulevard
Shares Outstanding 24 M Compensation Risk 9 Price Hint 4
Target High Price 2.00 Website https://aadibio.com 52 Week Change -0.5665
Average Volume 136417 Forward Eps -1.01 Recommendation Key none
Compensation As Of Epoch Date 1 B Quick Ratio 437.40 % Last Split Factor 1:15
Regular Market Day High 2.38 Is_sp_500 False Profit Margins -246.06 %
Debt To Equity 1.37 Fifty Two Week High 5.54 Day High 2.38
Shares Short 256468 Regular Market Open 2.33 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue -0.2180 Revenue Growth 21.00 %
Shares Percent Shares Out 0.0104 Operating Cashflow -54141000 Currency USD
Time Zone Full Name America/New_York Market Cap 56 M Is_nasdaq_100 False
Zip 90272 Quote Type EQUITY Industry Biotechnology
Long Name Aadi Bioscience, Inc. Overall Risk 7 Regular Market Day Low 2.27
Held Percent Institutions 0.4906 Current Price 2.28 Address2 Suite A250
Enterprise To Ebitda 0.0860 Financial Currency USD Current Ratio 4.89
Gross Margins -109.86 % Industry Disp Biotechnology Number Of Analyst Opinions 2
Country United States Float Shares 12 M Two Hundred Day Average 1.86
Governance Epoch Date 1 B Enterprise Value -5476946 Price To Sales Trailing12 Months 2.24
Forward PE -1.82 Regular Market Volume 77683 Ebitda -63395000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes.

Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway.

Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.